November 9, 2010 – In an effort to further promote the utility of PET/CT (positron emission tomography/computed tomography) imaging in assessing the effectiveness of oncology treatments, a new quantification tool is available to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Since the introduction of PERCIST, Siemens Healthcare Molecular Imaging created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of a metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient, so that these criteria will be clinically adopted and used in the field.

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity, often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single-pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

For more information: www.siemens.com/healthcare


Related Content

News | Radiation Therapy

May 14, 2025 — Siemens Healthineers is investing $150 million in new projects to expand production, create jobs and ...

Time May 15, 2025
arrow
News | Radiology Business

The issue of sustainability in healthcare has gained increasing focus over the past several years. During a 2022 plenary ...

Time May 06, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Computed Tomography (CT)

April 17, 2025 — Nano-X Imaging LTD has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Time April 18, 2025
arrow
News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | PACS

April 3, 2025 – Konica Minolta Healthcare Americas, Inc. has launched the next-generation of the Exa Platform with the ...

Time April 15, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
Subscribe Now